anti-PLK1 phospho (Thr210) antibody

anti-PLK1 phospho (Thr210) antibody for Western blot and Human,Rat

Cancer antibody; Cell Biology and Cellular Response antibody; Gene Regulation antibody


Product Description Rabbit Polyclonal antibody recognizes PLK1 phospho (Thr210)
Tested Reactivity Hu, Rat
Predict Reactivity Ms, Bov, Dog, NHuPrm, Xenopus laevis, Zfsh
Tested Application WB
Host Rabbit
Clonality Polyclonal
Isotype IgG
Target Name PLK1
Antigen Species Human
Immunogen Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr210 conjugated to KLH
Conjugation Un-conjugated
Alternate Names STPK13; Serine/threonine-protein kinase PLK1; EC; Serine/threonine-protein kinase 13; Polo-like kinase 1; PLK-1; PLK

Application Instructions

Application Suggestion
Tested Application Dilution
Application Note Specific for ~66k PLK phosphorylated at Thr 210. Immunolabeling of the PLK band is completely blocked by λ-phosphatase treatment.
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.


Form Liquid
Purification Affinity Purified
Buffer 10 mM HEPES (pH 7.5), 150 mM NaCl, 0.1 mg/ml BSA and 50% Glycerol
Stabilizer 0.1 mg/ml BSA, 50% Glycerol
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.


Database Links

GeneID: 25515 Rat PLK1

GeneID: 5347 Human PLK1

Swiss-port # P53350 Human Serine/threonine-protein kinase PLK1

Swiss-port # Q62673 Rat Serine/threonine-protein kinase PLK1

Gene Symbol PLK1
Gene Full Name polo-like kinase 1
Background Polo-like kinases are important regulators of cell cycle progression. PLK1 is a highly conserved Ser/Thr kinase that has essential roles in the formation of mitotic bipolar spindles (van Vugt et al., 2004). Deregulated expression of PLK’s is detected in many types of cancer and associated with oncogenesis (Takei et al., 2005). It has been proposed that PLK1 function is altered at different stages of mitosis through consecutive phosphorylation events at Ser137 and Thr210 (van de Weerdt et al., 2005).
Research Area Cancer antibody; Cell Biology and Cellular Response antibody; Gene Regulation antibody
Calculated MW 68 kDa
PTM Catalytic activity is enhanced by phosphorylation of Thr-210. Phosphorylation at Thr-210 is first detected on centrosomes in the G2 phase of the cell cycle, peaks in prometaphase and gradually disappears from centrosomes during anaphase. Dephosphorylation at Thr-210 at centrosomes is probably mediated by protein phosphatase 1C (PP1C), via interaction with PPP1R12A/MYPT1. Autophosphorylation and phosphorylation of Ser-137 may not be significant for the activation of PLK1 during mitosis, but may enhance catalytic activity during recovery after DNA damage checkpoint. Phosphorylated in vitro by STK10.
Ubiquitinated by the anaphase promoting complex/cyclosome (APC/C) in anaphase and following DNA damage, leading to its degradation by the proteasome. Ubiquitination is mediated via its interaction with FZR1/CDH1. Ubiquitination and subsequent degradation prevents entry into mitosis and is essential to maintain an efficient G2 DNA damage checkpoint. Monoubiquitination at Lys-492 by the BCR(KLHL22) ubiquitin ligase complex does not lead to degradation: it promotes PLK1 dissociation from phosphoreceptor proteins and subsequent removal from kinetochores, allowing silencing of the spindle assembly checkpoint (SAC) and chromosome segregation.

Images (1) Click the Picture to Zoom In

  • ARG52396 anti-PLK1 phospho (Thr210) antibody WB image

    Western blot: Rat synaptic membrane stained with ARG52396 anti-PLK1 phospho (Thr210) antibody showing specific immunolabeling of the ~66 k PLK protein phosphorylated at Thr210 (control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: λ-Ptase). The blot is identical to the control except that it was incubated in λ-Ptase (1200 units for 30 min) before being exposed to the phospho-Thr210 PLK antibody. The immunolabeling is completely eliminated by treatment with λ-Ptase.